Withdrawal Syndrome
9
1
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.1%
1 terminated out of 9 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Kratom Use Disorder Management Using Clonidine and/or Buprenorphine
Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.
Characterization of the Pattern of Consumption and Withdrawal Syndrome From Dual Cannabis and Tobacco Use
Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19
AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)
Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in PICU (TIP-15-01)
Early Rehabilitation in Critically Ill Children - The PICU Liber8 Study
Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses
Protocolized Sedative Weaning VS. Usual Care in Pediatric Critically Ill, RCT